Atea Pharmaceuticals AVIR Income Statement (2019-2026)

NASDAQ AVIR
$4.22 +0.02 (+0.48%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Atea Pharmaceuticals Quarterly Income Statement

Periods 29 quarters
Latest Sep 2026

Atea Pharmaceuticals reported net income of -$32.14M for the quarter ended Sep 2026. This income statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
192.18M
Operating items
Research & DevelopmentR&D
57.81M29.63M19.86M4.91M27.54M28.95M22.06M28.18M35.05M57.58M34.70M26.16M25.67M29.58M32.28M38.35M47.82M41.13M28.15M27.09M
Share-based Compensation (IS)Stock Comp.
12.59M12.72M12.16M14.30M6.95M4.67M4.52M4.59M3.73M3.38M3.47M
Selling, General & AdministrativeSG&A
13.19M12.54M12.44M11.38M12.36M12.62M13.17M12.60M11.53M12.23M12.22M11.04M13.36M9.46M9.07M7.22M7.12M6.87M6.95M6.92M
Operating ExpensesOpex
71.00M42.18M32.30M16.28M39.90M41.57M35.24M40.79M46.57M69.81M46.92M37.20M39.03M39.04M41.35M45.57M54.93M48.01M35.10M34.01M
Operating IncomeOp. Inc
121.18M-42.18M-32.30M-16.28M-39.90M-41.57M-35.24M-40.79M-46.57M-69.81M-46.92M-37.20M-39.03M-39.04M-41.35M-45.57M-54.93M-48.01M-35.10M-34.01M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.86M0.17M0.38M0.00M0.05M0.47M-0.39M-0.10M0.92M-0.41M-0.12M-0.08M0.20M-0.06M-0.27M0.00M0.02M
Interest & Investment IncomeInt & Inv Inc
0.05M0.10M1.08M4.38M5.59M6.30M7.30M7.86M7.76M6.87M6.64M6.28M5.71M4.97M4.39M3.71M3.30M2.62M2.19M1.89M
Net income details
EBIT
121.18M-42.18M-32.30M-16.28M-39.90M-41.57M-35.24M-40.79M-46.57M-69.81M-46.92M-37.20M-39.03M-39.04M-41.35M-45.57M-54.93M-48.01M-35.10M-34.01M
EBT
121.23M-42.08M-31.22M-11.90M-34.31M-35.27M-27.93M-32.92M-38.82M-62.94M-40.28M-30.93M-33.32M-34.07M-36.95M-41.85M-51.64M-45.39M-32.91M-32.12M
Tax ProvisionsTaxes
4.10M0.12M-3.83M0.12M0.20M0.25M0.22M0.35M0.23M0.24M0.23M0.23M0.20M0.21M0.20M-6.77M0.05M0.02M0.04M
Income After Tax
117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M-32.93M-32.16M
Income from Continuing OperationsIncome (Continuing)
117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M-32.93M-32.16M
Consolidated Net IncomeConsol Net Inc.
117.13M-42.08M-31.34M-8.92M-34.26M-35.09M-28.19M-33.09M-38.70M-63.56M-40.62M-30.23M-33.95M-34.39M-37.24M-41.85M-44.93M-45.71M-32.93M-32.14M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
117.13M-31.34M-8.92M-34.26M-28.19M
Income towards Parent CompanyParent Net Inc
117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M-32.93M-32.16M
Net Income towards Common StockholdersNet Income
117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-44.87M-45.44M-32.93M-32.16M
Additional items
EPS (Basic)
1.41-0.51-0.38-0.10-0.41-0.43-0.34-0.40-0.47-0.75-0.48-0.37-0.40-0.40-0.44-0.53-0.55-0.57-0.41-0.40
EPS (Diluted)
1.33-0.51-0.38-0.10-0.41-0.43-0.34-0.40-0.47-0.75-0.48-0.37-0.40-0.40-0.44-0.53-0.55-0.57-0.41-0.40
Shares Outstanding
82.82M83.18M83.26M83.26M83.25M83.33M83.40M83.40M83.39M83.92M84.25M84.42M84.26M85.16M83.75M79.05M81.50M79.20M80.05M80.22M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
88.25M83.18M83.26M83.26M83.25M83.33M83.40M83.40M83.39M83.92M84.25M84.42M84.26M85.16M83.75M79.05M81.50M79.20M80.05M80.22M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
83.10M83.26M83.26M83.29M83.29M83.40M83.40M83.44M83.44M84.22M84.42M84.46M84.46M85.58M81.14M78.13M78.13M80.03M80.20M80.30M
EBITDA
121.19M-42.17M-32.25M-16.18M-42.80M-44.55M-38.83M-45.00M-50.81M-73.19M-49.84M-39.69M-41.64M-40.68M-42.56M-46.54M-55.64M-48.49M-35.54M-34.30M
Tax Rate
3.38%

Atea Pharmaceuticals Income Statement API

Pull Atea Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AVIR&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY